Business Wire

Olympus Launches EVIS X1, its Most Advanced Endoscopy System to Date

Share

Olympus Corporation (President: Yasuo Takeuchi) today announced the launch of EVIS X1, its most advanced endoscopy system to date. The new system is to improve outcomes from disorders of the stomach, colon, and oesophagus, as well as from bronchial diseases, by providing every endoscopist with innovative and proven tools. The launch of EVIS X1 further strengthens Olympus’ leadership in endoscopy and continued medical focus.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200423005044/en/

EVIS X1 CV-1500 front (Photo: Business Wire)

EVIS X1 CV-1500 front (Photo: Business Wire)

EVIS X1 supports accurate screening and confident diagnosis through introducing new and easy-to-use technologies to support how gastrointestinal disorders, such as colorectal cancer (CRC), or bronchial diseases are detected, characterized and treated. These include Extended Depth of Field (EDOF), Red Dichromatic Imaging (RDI), Texture and Color Enhancement Imaging (TXI) as well as the already known and proven Narrow Band Imaging (NBI). Being committed to innovation, Olympus is also already developing future technologies – in particular featuring artificial intelligence (AI).

“EVIS X1 is the latest innovation to build on our 100-year legacy of world-leading innovation and quality,” said Frank Drewalowski, Head of Endoscopic Solutions Division, Olympus Corporation. “We are proud that, with EVIS X1, we can support endoscopists around the world and help to elevate the standard of endoscopy across the board.”

Combining knowledge, experience and innovation in one endoscopic system

The key features of the EVIS X1 system include:

  • Extended Depth of Field (EDOF): EDOF combines two images at different focal lengths into one perfect image to help aid diagnosis and confident decision-making. It delivers observational excellence through continuous broad focus and seamless magnification. At the same time, the established Dual Focus function provides high magnification, which can be activated by the push of a button. This improved visibility and continuously sharp image has been developed to reduce the necessity for focal adjustments and could improve efficiency and decrease the oversight rate.
  • Red Dichromatic Imaging (RDI): Gastrointestinal bleeding is a serious challenge, potentially involving considerable mortality and management costs. RDI enhances the visibility of deep blood vessels and GI bleeding sources, thereby helping to identify blood vessels that could require immediate treatment. It utilizes green, amber and red wavelengths to visualize deep blood vessels. Easier identification of bleeding spots makes hemostasis quicker and easier whilst potentially improving the efficiency of any corresponding treatment. This minimally invasive technology could also help reduce physician stress during endoscopic therapy.
  • Texture and Color Enhancement Imaging (TXI): TXI supports better visibility of potential and extant lesions (such as areas of inflammation, flat or depressed lesions, or even tiny precursor lesions) through enhancing texture, brightness and color to define subtle tissue differences more clearly. With its advanced imaging technology, TXI holds the potential to reinvent white light in endoscopy. By supporting better visibility of potential and extant lesions, TXI aims to contribute to higher detection rates and improve qualitative diagnosis.
  • Narrow Band Imaging (NBI): NBI is an already known, powerful and proven optical technology that allows for a high-confidence optical diagnosis through the creation of a strong contrast between vessels and surrounding mucosa. It utilizes specific blue and green wavelengths. NBI not only supports earlier detection of any lesions but also provides a more detailed, higher-contrasted visualization and thus improves qualitative diagnosis.

Being ready for the future

The next upcoming feature of the EVIS X1 system will be AI. Olympus is developing innovative new ways to integrate breakthroughs in deep learning into the world of image detection, characterization, staging, and treatment.

Beyond introducing new features, EVIS X1 also provides newly established cross-compatibility between two formerly separate systems: EVIS LUCERA ELITE and EVIS EXERA III. This means that Olympus’ existing range of products can be combined to provide an extended portfolio of endoscopes for special procedures – expanding the possibilities for endoscopists.

Focusing on colorectal cancer prevention

Especially by helping to facilitate screening and early detection of abnormalities in the gastrointestinal tract, EVIS X1 could play a major role in the prevention of colorectal cancer (CRC). In 2018, there were 1.80 million cases of colorectal cancer and 862,000 patient deaths worldwide.i It is also expected that the global burden of CRC will increase substantially by 2030.ii For every 1% increase in adenoma detection rate (ADR), there is a 3% decrease in CRC risk.iii

“Early detection and diagnosis is critical for CRC prevention,” said Prof. Michal F. Kaminski, Professor at the National Research Institute of Oncology in Warsaw. “EVIS X1 is intuitive and gives endoscopists a range of innovative and proven tools to carry out minimally invasive, precise and effective procedures – enabling them to make truly-informed diagnostic and treatment decisions in the best interest of their patients. Among the new technologies especially TXI looks promising. It seems to provide more information to the endoscopist while maintaining a close to white light appearance. This will make it very easy to adapt to it.”

Reaffirming leadership in endoscopy

EVIS X1 is not only anticipated to serve healthcare professionals, hospital management and patients around the world but also follows Olympus’ implementation of its strategy. “Our purpose is to make people’s lives healthier, safer and more fulfilling,” said Takaharu Yamada, Vice President, GI Endoscopy Business, Global, Olympus Corporation. “This launch also strengthens our global leadership in endoscopy and follows our focus of the corporate portfolio centering on the medical business.”

EVIS X1 is initially being launched in EMEA (Europe, Middle East & Africa), Australia, India and Hong Kong. It is manufactured by Olympus Medical Systems Corporation. The company and product names specified in this release are the trademarks or registered trademarks of Olympus.


About Olympus

Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries, as well as cameras and audio products. For more than 100 years, Olympus has focused on making people’s lives healthier, safer, and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, ensuring public safety, and capturing images of the world.

Olympus Endoscopic Solutions uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with the world’s first gastrocamera in 1950, Olympus’ endoscopic portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, as well as systems integration solutions and medical services.

> For more information, please visit: www.olympus-global.com

About EVIS X1

> For further information about EVIS X1, please visit: www.olympus.eu/evisx1

> For regular updates and engagement, please follow us on social media at:

References

i WHO Cancer Factsheet. Available: https://www.who.int/news-room/fact-sheets/detail/cancer . Accessed February 2020.
ii Global patterns and trends in colorectal cancer incidence and mortality. https://gut.bmj.com/content/66/4/683 . Accessed February 2020.
iii Corley DA, Jensen CD, Marks AR, et al. Adenoma Detection Rate and Risk of Colorectal Cancer and Death. N Engl J Med. 2014;370:1298–1306. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036494/ . Accessed February 2020.

Contact information

For questions or additional information, please contact:

Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com

Japan
Yuka Horimoto
+81-90-2490-1071
yuka_horimoto@ot.olympus.co.jp

Asia Pacific
Davis Li
+852-2586-7852
davis.li@fleishman.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF to Webcast Fireside Chat at Stifel Virtual Cross Sector Insight Conference June 82.6.2020 23:15:00 EESTPress release

Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced that the Company’s management will be participating in a fireside chat at the Stifel Virtual Cross Sector Insight Conference on Monday, June 8, 2020 at 4:00 PM ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005897/en/ Contact information Mich

ZOOM International to Begin Doing Business As Elevēo2.6.2020 17:00:00 EESTPress release

ZOOM International a worldwide leader in omni-channel compliance recording, workforce optimization (WFO), and revenue protection software for contact centers will begin doing business solely as elevēo beginning June 2nd, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005093/en/ For over 20 years, ZOOM International has been a leading workforce optimization software provider in the contact center industry. Very early on, we were approached to solve a compliance problem with call recording. We built a creative software solution in record time, and began a journey crossing continents, employing hundreds of colleagues, and eventually improving operations, compliance, and customer experience for thousands of customers in 94 countries via more than 550 channel partners in the communications industry. Over time we have earned an 88 NPS score from ZOOM International customers & partners for our world-class support and in

Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board2.6.2020 17:00:00 EESTPress release

DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes. Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts fro

Andersen Global Expands Presence in Qatar2.6.2020 16:30:00 EESTPress release

Andersen Global announced its collaboration with Doha-based tax firm MS Partner, adding depth to the organization’s presence in Qatar and expanding its global platform. MS Partner was founded in 2018 and includes two Partners and more than 10 professionals that specialize in providing tax services to a variety of international clients including individuals and companies – both private and public. MS Partner’s Chairman His Excellency Shaikh Sultan Bin Jassim Bin Mohammed Al Thani is a prominent business leader in the State of Qatar. “We value our clients and people, and maintain the highest of professional standards,” said Office Managing Director Manikandan Rajan. “We’ve watched Andersen Global grow regionally as well as globally, and the organization has set the standard for providing clients with best-in-class service in an independent and seamless manner. We look forward to working closely with our fellow collaborating firm in Doha, Al-Khalifa Law, as well as all the collaborating f

Pegasus Development AG: Pegasus Present Its New Brand Pegastril - Nuevo2.6.2020 16:06:00 EESTPress release

The coronavirus pandemic harbours the potential for enormous growth in specific industries. To that end, however, it's important to identify which markets will be dominant in the future. One of the key growth sectors is the production and distribution of disinfectants and associated technologies. Regardless of whether a cure for, or vaccine against, COVID-19 is developed, protection against viruses and bacteria has become incredibly important across the globe and will continue to be a concern going forward. This was one of the reasons why Pegasus Development AG decided to partner with the British disinfectant manufacturer Nuevo. One of the decisive factors choosing Nuevo was its highly competitive product, which is free from alcohol, animal products, perfume, essential oils or dyes. Furthermore, the product has already been tested according to the highest stipulations of the European standard EN 1276, is manufactured according to the latest regulations of the European Biocides Directiv

PVH Corp. Announces Leadership Update at Tommy Hilfiger and PVH Europe2.6.2020 16:00:00 EESTPress release

PVH Corp. (NYSE:PVH), owner of a portfolio of iconic brands including TOMMY HILFIGER and CALVIN KLEIN, announced today that Daniel Grieder is stepping down from his role of Chief Executive Officer, Tommy Hilfiger Global & PVH Europe after 23 years in various management roles within the organization, and will be leaving the company to pursue other interests. Martijn Hagman will succeed Grieder and become the new Chief Executive Officer, Tommy Hilfiger Global & PVH Europe, effective June 2, 2020. Hagman is currently Chief Operating Officer, Tommy Hilfiger Global & PVH Europe and Chief Financial Officer, Tommy Hilfiger Global, overseeing operations, finance, digital business transformation, technology, business development and the Tommy Hilfiger global sustainability program. He is a 12-year veteran of the Tommy Hilfiger leadership team and has been instrumental in Tommy Hilfiger’s impressive global expansion and the strategy that has led to PVH Europe’s consistent year-over-year growth.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom